Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLPT 
Clearpoint Neuro Inc (CLPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29
1 Year Target Price $29
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.93% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 298.20M USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 2 | Beta 0.89 | 52 Weeks Range 9.76 - 19.22 | Updated Date 09/15/2025 |
52 Weeks Range 9.76 - 19.22 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -66.15% | Operating Margin (TTM) -61.64% |
Management Effectiveness
Return on Assets (TTM) -24.52% | Return on Equity (TTM) -85.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 292118604 | Price to Sales(TTM) 8.88 |
Enterprise Value 292118604 | Price to Sales(TTM) 8.88 | ||
Enterprise Value to Revenue 8.7 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 28427400 | Shares Floating 25974415 |
Shares Outstanding 28427400 | Shares Floating 25974415 | ||
Percent Insiders 8.19 | Percent Institutions 38.99 |
Upturn AI SWOT
Clearpoint Neuro Inc
Company Overview
History and Background
ClearPoint Neuro, Inc. (CLPT) was founded in 1998 as MRI Interventions, Inc. and later changed its name in 2020. The company focuses on developing and commercializing innovative platforms for targeted drug delivery and gene therapy to the brain and other organs.
Core Business Areas
- Neuro Navigation: Provides real-time, MRI-guided navigation systems for minimally invasive neurosurgery. Enables precise delivery of therapies to specific brain targets.
- Drug Delivery: Offers solutions for targeted drug delivery, including cannulas and infusion pumps optimized for delivering therapeutics directly to the brain.
- Biologics and Gene Therapy: Partners with pharmaceutical and biotechnology companies to support clinical trials involving gene therapies and biologic agents for neurological disorders.
Leadership and Structure
Joe Burnett is the CEO. The organizational structure includes departments focused on research and development, sales and marketing, clinical operations, and manufacturing. The Board of Directors guides the company's strategic direction.
Top Products and Market Share
Key Offerings
- ClearPoint SmartFlow Cannula: A critical component of the ClearPoint system, allowing for precise drug delivery directly into the brain for therapies such as gene therapy. Again, precise market share data is not generally disclosed. Its competitor is the convection enhanced delivery (CED) from companies like Renishaw.
- ClearPoint System: A neuro-navigation platform used for minimally invasive neurosurgery, including placement of deep brain stimulation (DBS) leads, laser ablation, and drug delivery. Market share data is not readily available publicly. Competitors include Medtronic and Boston Scientific in the DBS space and Monteris Medical in laser ablation.
Market Dynamics
Industry Overview
The neurosurgery and drug delivery markets are experiencing growth driven by advancements in technology, increasing prevalence of neurological disorders, and rising demand for minimally invasive procedures.
Positioning
ClearPoint Neuro is positioned as a leader in MRI-guided neuro-navigation and targeted drug delivery, with a focus on precision and minimally invasive techniques. Its competitive advantage lies in its real-time MRI-guidance capabilities and its partnerships with pharmaceutical companies.
Total Addressable Market (TAM)
Estimates for the total addressable market for neuromodulation and targeted drug delivery range in the billions of dollars. ClearPoint is focused on capturing a significant share of this market through its innovative platform and strategic partnerships. Specific TAM values vary depending on the sources and the specific segment included.
Upturn SWOT Analysis
Strengths
- Proprietary MRI-guided neuro-navigation platform
- Strong relationships with leading pharmaceutical and biotechnology companies
- Minimally invasive approach reduces patient morbidity and recovery time
- Experienced leadership team
Weaknesses
- Limited market share compared to established players
- Reliance on partnerships for revenue generation
- Potential for regulatory hurdles in new product development
Opportunities
- Expanding applications of the ClearPoint platform to new neurological disorders
- Increasing demand for gene therapy and targeted drug delivery
- Potential for strategic acquisitions to expand product portfolio
- Further penetration into international markets
Threats
- Competition from established medical device companies
- Potential for technological obsolescence
- Changes in reimbursement policies
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- BSX
- MRON
Competitive Landscape
ClearPoint Neuro's competitive advantage lies in its MRI-guided neuro-navigation technology. However, it faces competition from larger, more established medical device companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced revenue growth driven by increasing adoption of its ClearPoint system and strategic partnerships.
Future Projections: Analysts project continued revenue growth for ClearPoint Neuro based on the increasing demand for minimally invasive neurosurgery and targeted drug delivery. Projections vary based on analyst and market conditions.
Recent Initiatives: Recent initiatives include expanding partnerships with pharmaceutical companies, developing new applications for the ClearPoint platform, and seeking regulatory approvals for new products.
Summary
ClearPoint Neuro is a growing company in the neuro-navigation and drug delivery space, poised to benefit from advancements in gene therapy and minimally invasive procedures. While they have innovative technology and strategic partnerships, they face competition from larger companies and need to manage their cash burn effectively. Key strengths are their MRI-guided system and pharma partnerships. The company needs to watch out for competition and reimbursement hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Materials
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary depending on the source. Financial data is dynamic and should be verified with the company's official financial statements.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearpoint Neuro Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2020-02-12 | President, CEO & Director Mr. Joseph Michael Burnett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 115 | Website https://www.clearpointneuro.com |
Full time employees 115 | Website https://www.clearpointneuro.com | ||
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.